by Paul Fassa
Health Impact News

Dr. Stanislaw Burzynski, M.D., established his Burzynski Institute for cancer research and healing in Houston, TX, the same city that hosts the prestigious MD Anderson Cancer Center. Originally from Poland, Dr. Burzynski has been researching and developing a unique approach for curing cancer since 1976.

His approach avoids the carpet bombing chemotherapy of conventional oncology that destroys healthy cells as well as cancer cells. Nor does it involve radiation or surgery, and there are little to no side effects.

He has developed biochemical agents to “shut off” genes that promote tumors and sustain cancer cells. Those biochemical agents are called antineoplastons.

Antineoplastons are derived from animal blood and urine containing naturally occurring peptides and amino acid derivatives that activate tumor-suppressing genes or deactivate tumor supporting genes. The antineoplastons are not toxic or carcinogenic, like chemotherapy and radiation.

During his tightly monitored FDA approved human trials, using cancer patients that mainstream oncology has failed, Dr. Burzynski has had several successes, including permanent remissions, with patients from 20 years ago still cancer free today.

His most impressive results have been with patients stricken with Glioblastoma Multiforme (GBM) stage IV brain cancer, a cancer mainstream oncology has had no success with.

After several years of FDA trial restrictions and medical bureaucratic harassment by the Texas Medical Board (TMB) through the courts system, it appeared that Dr. Burzynski was completely cleared in 2012 of all charges brought against him.

The final court decisions that favored Burzynski were upheld in higher courts despite TMB appeals. It was a long, costly and bitter battle, with many former cancer free patients coming to testify on behalf of Dr. Burzynski’s treatment authenticity and efficacy.

The Veracity of Burzynski’s Treatment Was Confirmed

Was the medical establishment after Dr. Burzynski because his antineoplaston approach does not work? Several testimonials from former and current patients say otherwise. Dismissing living proof as merely anecdotal was put aside by an independent Japanese research group.

Dr. Hideaki Tsuda, M.D. with the Kurume Medical University in Japan stated:

“After 27 years of independently testing antineoplastons—including randomized clinical trials, we found that Dr. Burzynski was right. It’s obviously not anecdotal anymore.”

Here’s one of the published studies.

Yet the TMB is After Burzynski Again

The charges are different this time. Instead of attacking his ingenious new antineoplaston approach, they’re charging him and his immediate staff of personal misconduct within various medical guidelines with the intention of removing their medical licenses. His immediate staff includes his M.D. son Gregory Burzynski, as well as Zanhua Yi and Alejandro Marquis.

One would think the “War On Cancer” would be willing to look into promising new therapies instead of harassing those who innovate them. Evidently the high profits from dangerous drugs and radiation therapies are preventing further investigation. Yet their drugs and radiation treatments have been very unsuccessful.

The late Dr. Nicholas Gonzalez, who had further developed the pancreatic enzyme therapy for cancer originated in the 1970s by Dr. William Kelly stated:

‘War on cancer’ has been a failure due to a combination of politics, money, greed, and corruption—largely the result of an unholy alliance between the American Cancer Society, NCI [National Cancer Institute], Sloan-Kettering, and the drug companies. (Source)

The lost war on cancer has even been declared from within the ranks. University of Michigan M.D. researcher Dr. Max Wicha admitted to mainstream media’s Pittsburgh Post-Gazette that cancer recurrences are more common than cures because mainstream oncology hasn’t been able to rid cancer stem cells.

Here’s how that February 24, 2010 Pittsburgh article titled “Cancer expert tells how treatment can be problem” began:

Max Wicha is coming to Pittsburgh today to deliver a startling message. Standard cancer treatments not only often fail to eradicate cancer, but can make it worse. (Emphasis added by author)

The five year cancer free standard used by mainstream oncology allows a recurrence after that five year threshold to be considered a new cancer. Statistically, many don’t make it even to that threshold. Most alternative cancer therapies, including Dr. Burzynski’s methods, easily exceed the five years cancer free mark.

From an earlier Health Impact News article, “Cancer Makes Too Much Money to Cure”:

In a patent that was designed to steal Dr. Burzynski’s cancer cure, the United States Government, stated, ‘Current approaches to combat cancer rely primarily on the use of chemical and radiation, which are themselves carcinogenic and may promote recurrences and the development of metastatic disease.’

[Thus] The U.S. Government admits that conventional treatments cause cancer. (Patent No. 5,605,930. “Compositions and methods for treating and preventing pathologies including cancer.” Approved 1997 USA Department of HHS page 56)

The central issue appears to be that Dr. Burzynski is not affiliated with a pharmaceutical company, but he owns the patents for his antineoplastons. In 1982, Dr. Richard Crout, Director of the FDA’s Bureau of Drugs is reported to have stated:

I never have and never will approve a new drug to an individual, but only to a large pharmaceutical firm with unlimited finances. (Source)

Dr. Burzynski is an individual who has done all his own research and patented all of his antineoplastins. He has been seeking FDA approval despite all the obstacles the FDA and others have used to distract him, cause his trials to fail, or simply remove his medical certification.

Burzynski’s extensive genome analysis to determine which antineoplastons should be used to promote genes that shut off cancer cells is less expensive than before and currently mostly covered by private and public insurers. Sometimes he has used conventionally approved cancer drugs “off label,” which is not illegal, according to what he determines from his genome analysis.

Off label means a drug, though approved, wasn’t approved for the specific application used. It is a fairly common practice in mainstream medicine.

Whenever cancer patients didn’t fully qualify for his antineoplaston treatments according to FDA phase 2 trial guidelines, Dr. Burzynski offered an FDA approved drug off label, phenylbutyrate, which he discovered the body metabolizes into one of the main ingredients of antineoplastons.

Some who are aware of Dr. Burzynski’s situation claim the effort to get rid of Burzynski or at least prevent cancer patients from using his treatments was intended to allow a giant pharmaceutical company easy access to his patents or at least protect the business of cancer.

This scheme was disclosed near the end of the original Burzynski documentary: “Cancer is Serious Business” available at the end of this article.

FDA Denying Patients Antineoplaston Therapy

Dr. Burzynski’s FDA phase II guidelines were revised after 2012 when the attempts to jail Dr. Burzynski had failed. His clinic was no longer able to accept children as patients, even after he had cured children with terminal brain cancer. In 2013, the FDA extended the ban to adults, effectively shutting down new patient access to Burzynski’s clinic.

The only hope of dying patients was to convince the FDA to grant a “compassionate use” exemption. This rule allows for the case-by-case use of an experimental or unapproved drug outside of a clinical trial if a patient has a serious or immediately life-threatening disease or condition, and has no other treatment options left.

Part of gaining that approval is proving the risk is no worse than approved treatments. Yet the FDA, despite acknowledging antineoplastons’ safety compared to chemotherapy, claims they consider antineoplastons dangerous because they claim they’re unworkable.

A five year old died from aggressive brain cancer while waiting for the FDA to approve antineoplaston treatment. By the time he was granted approval, he was already brain dead. (Source)

It’s apparent that Dr. Burzynski’s paradigm shift threatens mainstream oncology’s multi-billion dollar monopoly if his patents aren’t co-opted by pharmaceutical companies. It has cost him dearly, both financially and emotionally. It’s amazing that he’s held up as long as he has to achieve amazing breakthroughs.

The most recent trial has begun in Austin, TX and is scheduled throughout 2016. There are four medical practitioners from the Burzynski Institute, including Dr. Burzynski, who are defendants.

Below is the first Burzynski documentary: “Cancer is Serious Business.” Something very interesting is disclosed after the one hour mark, and especially at the hour and forty minute mark.

For more details, video updates from cancer patients cured by Dr. Burzynski, and online actions or tracking you can take, go here. For more background on this saga, use the sources and related articles below:

Sources:

Dying Patients Denied Access to Life-Saving Cancer Treatment

The Cancer Industry is Too Prosperous to Allow a Cure

Dr. Burzynski’s Cancer Cure the FDA Tried to Suppress

Purchase both DVDs

Free Shipping Available! Click Here.

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : $9⁹⁹
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.